In this review:
Axicabtagene ciloleucel for RR DLBCL
Tisagenlecleucel for relapsed aggressive B-cell non-Hodgkin lymphoma
Axicabtagene ciloleucel vs tisagenlecleucel for RR DLBCL
GPRC5D-targeted CAR T for RRMM
Talquetamab, GPRC5D + CD3 bispecific antibody in RRMM
Cevostamab monotherapy in heavily pretreated RRMM
Ultra-high-risk NDMM and primary plasma cell leukaemia treatment
Autologous haematopoietic cell transplantation in MM
A CD38 and CD47 bispecific antibody innate cell modulator for RRMM
Lenalidomide, bortezomib, dexamethasone + isatuximab for MM
Please login below to download this issue (PDF)